Fortress Biotech Stock News

SCOTTSDALE, Ariz., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that focuses on the development and

SCOTTSDALE, Ariz., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (Journey Medical), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, and a subsidiary of Fortress Biotech, Inc. (NASDAQ: FBIO) (Fortress), today announced the closing of its initial public offering of common stock of 3,520,000 shares at a public offering price of $10.00 per share, for gross proceeds of $35.2 million, before deducting underwriting discounts and offering expenses. All of the shares of common stock were offered by Journey Medical.

Fortress Biotech (NASDAQ:FBIO) announced its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing the Zacks consensus estimate of ($0.08) by ($0.06), Fidelity Earnings reports. Fortress Biotech had a negative net margin of 63.05% and a negative return on equity of 15.34%. NASDAQ:FBIO traded down $0.10 during trading hours []

Fortress Biotech (FBIO) delivered earnings and revenue surprises of -225.00% and 14.52%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Net revenue for third quarter of 2021 increased 123% year-over-year to $21.1 million, a quarterly record

Fortress Biotech (FBIO) delivered earnings and revenue surprises of -225.00% and 14.52%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Journey Medical Corporation: Fortress Biotech Subsidiary Files For IPO

NEW YORK, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or mone

The stock price of Fortress Biotech (NASDAQ: FBIO) increased by over 6% this past week. This is why it happened.

NEW YORK and SOLANA BEACH, Calif., Oct. 13, 2021 /PRNewswire/ -- Cyprium Therapeutics, Inc. ("Cyprium"), a Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress") partner company, with support from its li

Cyprium Therapeutics, a partner company of Fortress Biotech (FBIO), reports positive data from two pivotal studies evaluating CUTX-101 in patients with Menkes disease.

Cyprium Therapeutics, a partner company of Fortress Biotech, is developing CUTX-101 for the treatment of Menkes disease

Triggers upfront payment of approximately $150 million to Caelum shareholders, of which approximately $64 million is payable to Fortress Biotech 1

NEW YORK and SCOTTSDALE, Ariz., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”), a partner company of Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”) focus